2nd Human Challenge Trials Conference


2nd Human Challenge Trials Conference
Venue: Hilton Hotel, Rockville, Maryland
September 28-30, 2017


Our world needs safer, more effective drugs and vaccines to prevent and treat infectious diseases.  Controlled human infections (CHIs) have served as an effective tool to promote this objective. For example, CHIs have led to progress in developing interventions against respiratory pathogens, enteric pathogens, and parasites. The most frequent application is the conduct of human challenge trials (HCTs), which can safely assess the value of novel or improved drugs and vaccines much more rapidly and efficiently than field trials, particularly if efficacy against CHI bridges to the field.  Progress against an infectious threat is greatly hampered when the field lacks a supporting human challenge model, such as is the case for human immunodeficiency virus and Mycobacterium tuberculosis.

Based on the premise that optimal use of CHIs is one of the best, most efficient ways to achieve rapid progress against infectious diseases, IABS is hosting a workshop to review the use of HCTs to promote the development of new drugs and vaccines, the benefits and risks of this approach, the regulatory framework within which HCTs are conducted, and novel CHI applications that would open new translational pathways.  This workshop follows two and a half years after the first such workshop hosted by IABS in Strasbourg, France, September 2014.

You may now register for this conferenceClick here to register and learn more about the meeting


International Alliance for Biological Standardization

Twitter Feed

#IABS #HUMANCHALLENGETRIALS. #MyronLevine presents #HTCs Perspectives and Current Issues. Register at : https://t.co/f5eiaCgM2T
#IABS#AUTOGENOUSVACCINES and their role in #ANIMALHEALTHSTRATEGY: differences to minor markets/minor use(#MUMS) emergency-regular licensing
Follow IABS_global on Twitter

Contact Info

IABS, Rue de la Vallée, 3
CH-1204 Geneva

+ 41 22 301 10 36
+ 41 22 301 10 37
This email address is being protected from spambots. You need JavaScript enabled to view it.